This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. 
Other treatments received by patients during trial follow up

Treatment
Immediate RT n (%). n=102
Deferred RT, n (%). n=101
Chemotherapy 
Median overall survival from diagnosis of mesothelioma to death
Median overall survival from diagnosis of mesothelioma was 388 days (95% CI not estimable) in the immediate radiotherapy group and 400 days (not estimable) in the deferred radiotherapy group (from diagnosis hazard ratio 1·02, 95% CI 0·70-1·50; p=0·900). Failure to give radiotherapy when indicated according to the protocol 3 (clinical decline) 7 (2 patients had PTM diagnosed at 12 month follow up, therefore completed trial before radiotherapy given; 2 patients were too unwell to receive radiotherapy at time of PTM diagnosis; 1 patient declined radiotherapy; 2 missing data) Radiotherapy given out of the stipulated time-frame 4 (given >42 days after procedure) 1 (given >42 days after PTM diagnosis)
Radiotherapy received
Radiotherapy field margin smaller than that stipulated in the protocol (ie <7x7cm) 8 (field <7cm in either width or length) 0
Other major radiotherapy protocol deviation 0 2 (2 patients given 10Gy in 1# to treat PTM) RT= Radiotherapy; kv= kilovolts; MV= megavolts. * This patient received radiotherapy for a chest nodule >7cm from the pleural intervention site, however, this was not formally identified at clinical examination during a SMART trial visit and hence was not included for the purposes of the trial analysis.
Radiotherapy Quality Assurance (QA) for the trial
Advice regarding the radiotherapy QA for the trial was obtained from the NCRI Radiotherapy Trials QA Group at the start of the trial in January 2012, who reviewed the protocol and case report forms. As the standard radiotherapy technique in the trial was a single field with no CT planning, they advised that the QA requirement was minimal. Based on their recommendations, we undertook the following QA:
1. Obtained evidence of an independent audit measurement from all the centres delivering radiotherapy within the last 5 years for the selected treatment modality for the trial.
2. A data query was raised for any field size smaller than 7x7cm.
Audit of compliance with the radiotherapy protocol during recruitment period
Overall the NCRI Radiotherapy Trials QA Group stated: "we would not recommend any specific pre-trial or on-trial QA beyond the independent audit check and collection of data on the CRF."
Details of the radiotherapy technique for the four patients in the immediate radiotherapy arm who were excluded from the per-protocol analysis and developed a PTM
In 3/4 cases, the radiotherapy field size was smaller than that stipulated in the protocol (instead of a minimum field size of 7x7cm, the field sizes were: 6x8cm, 6x6cm and 6x7cm). Two of them were treated with electrons and one was treated with kv photons. All had 21Gy in 3 fractions delivered within 42 days of their pleural intervention.
One patient was randomised 36 days after their pleural intervention (ie >35 days post procedure, hence the protocol violation). However the first fraction of radiotherapy was given within the 42 day window. They received 21Gy in 3#s which was delivered using electrons. The field size was 8x8cm.  Itching around site * Mean score generated by assuming following scores: Not at all=1; a little=2; quite a bit=3; very much=4.
